 | Tofacitinib | IC50 | 2.2 [1] |
| Tofacitinib | Ki | 0.24 [1], 0.4 [2], 1.0 [3] |
 | Ruxolitinib | IC50 | 428.0 [1] |
| Ruxolitinib | Ki | 3.2 [1], 3.22 [2] |
 | Staurosporine | IC50 | 1.0 [1] |
 | 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one | IC50 | 33.0 [1] |
| 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one | Ki | 6310.0 [1] |
 | Ibrutinib | IC50 | 10.4 [1], 16.1 [2], 100.0 [3], 146.0 [4] |
 | Baricitinib | IC50 | 25.0 [1], 400.0 [2], 787.0 [3], 8000.0 [4] |
 | Pyridone 6 | IC50 | 5.0 [1], 10.0 [2], 900.0 [3] |
 | 3-[5-[4-(2-Hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)pyrrole-2,5-dione | IC50 | 0.5 [1], 1.0 [2], 8.0 [3], 11.0 [4], 525.0 [5] |
 | Filgotinib | IC50 | 194.7 [1], 810.0 [2], 10000.0 [3] |
 | N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide | IC50 | 605.0 [1], 8000.0 [2], 10000.0 [3] |
 | [(1S)-6-(5-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 0.7 [1], 49.0 [2], 458.0 [3], 10000.0 [4] |
 | 1-[(3Ar,7aR)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridin-6-yl]prop-2-en-1-one | IC50 | 0.4 [1], 47.0 [2], 116.0 [3], 399.0 [4] |
 | 1-[(3R)-3-(7H-Pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one | IC50 | 0.7 [1], 56.0 [2], 107.0 [3], 580.0 [4] |
 | N-[3-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]prop-2-enamide | IC50 | 0.3 [1], 29.0 [2], 32.0 [3], 2280.0 [4] |
 | [(1S)-1-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydroinden-1-yl]cyanamide | IC50 | 0.7 [1], 56.0 [2], 5480.0 [3] |
 | [(1S)-6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 3.0 [1], 256.0 [2], 598.0 [3], 10000.0 [4] |
 | [(1S)-6-[5-[3-(Hydroxymethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 0.5 [1], 78.0 [2], 498.0 [3], 10000.0 [4] |
 | N-[3-[5-(2-Methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]prop-2-enamide | IC50 | 0.5 [1], 31.0 [2], 63.0 [3], 953.0 [4] |
 | 2,2-Difluoro-6-[5-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-3H-1,4-benzoxazine-4-carbonitrile | IC50 | 3.0 [1], 162.0 [2], 456.0 [3], 7252.0 [4] |
 | 2-PropenaMide, N-[cis-4-[4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]cyclohexyl]- | IC50 | 8278.0 [1], 10000.0 [2] |
 | Decernotinib | IC50 | 1.2 [1], 2.5 [2] |
| Decernotinib | Ki | 2.5 [1] |
 | 3-(2-Aminoquinazolin-6-Yl)-4-Methyl-N-[3-(Trifluoromethyl)phenyl]benzamide | IC50 | 20.0 [1] |
 | JAK3 covalent inhibitor-1 | IC50 | 11.0 [1], 331.0 [2], 10000.0 [3] |
 | 1-(2-Aminoethyl)-2-(4-piperidinyl)-1H-benzoimidazole-5-carboxamide | IC50 | 1260.0 [1], 1300.0 [2], 232500.0 [3] |
 | 2-Cyano-3-[5-(3-cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]-N,N-dimethylprop-2-enamide | IC50 | 0.13 [1], 2.0 [2], 9.0 [3] |
 | 3-[(3R)-3-(4,5-Dimethoxy-8-oxo-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-9-yl)piperidin-1-yl]-3-oxopropanenitrile | IC50 | 2.55 [1], 15.3 [2], 1550.0 [3] |
 | 9-Cyclohexyl-4,5-dimethoxy-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one | IC50 | 2.92 [1], 65.9 [2], 3720.0 [3] |
 | N-[(1R,3S)-3-(Cyanoamino)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]methanesulfonamide | IC50 | 0.9 [1], 38.0 [2], 2240.0 [3] |
 | [(1S,3R)-3-Hydroxy-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 1.0 [1], 163.0 [2], 1728.0 [3] |
 | 1-Cyclopropyl-N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]methanesulfonamide | IC50 | 8000.0 [1], 10000.0 [2] |
 | 4-[[4-(4,5,6,8,10-Pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-3-yl)cyclohexyl]amino]benzonitrile | IC50 | 460.0 [1], 660.0 [2], 1000.0 [3] |
 | 4-(4,5,6,8,10-Pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-3-yl)-N-(2-phenylethyl)cyclohexan-1-amine | IC50 | 870.0 [1], 1000.0 [2] |
 | 4-Fluoro-N-[4-(4,5,6,8,10-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-3-yl)cyclohexyl]aniline | IC50 | 260.0 [1], 420.0 [2], 560.0 [3] |
 | Canertinib | IC50 | 2000.0 [1], 3880.0 [2] |
 | 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline | IC50 | 3140.0 [1], 10000.0 [2] |
 | 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea | IC50 | 1.0 [1], 1.1 [2] |
 | Oclacitinib | IC50 | 95.1 [1] |
 | CID 57336812 | IC50 | 84.7 [1], 150.0 [2] |
 | Spebrutinib | IC50 | 22.5 [1], 1753.0 [2] |
 | 9-(1-Methylpyrazol-4-yl)-1-(1-prop-2-enoyl-2,3-dihydroindol-6-yl)benzo[h][1,6]naphthyridin-2-one | IC50 | 3336.0 [1], 5180.0 [2] |
 | 2,6-Dichloro-N-{2-[(Cyclopropylcarbonyl)amino]pyridin-4-Yl}benzamide | Ki | 253.0 [1] |
 | [2-[6-(2-Ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-(5-piperidin-1-ylpyrazin-2-yl)methanone | IC50 | 0.5 [1], 59.9 [2] |
 | 9-(Cyclohexylmethyl)-4,5-dimethoxy-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one | IC50 | 1.65 [1], 76900.0 [2] |
 | 2-Methyl-N-[2-[3-(prop-2-enoylamino)anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide | IC50 | 1705.0 [1], 2680.0 [2] |
 | CID 11993785 | IC50 | 5.1 [1] |
 | 4-[1-(Oxiran-2-ylmethyl)triazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine | IC50 | 35.0 [1] |
 | Unii-7N5LJ2Z26C | IC50 | 35.0 [1], 220.0 [2] |
 | 5-Fluoro-2-[[(1S)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile | IC50 | 7.0 [1], 15.0 [2] |
 | N-[(2R)-1-(3-Cyanoazetidin-1-yl)-1-oxopropan-2-yl]-2-cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide | IC50 | 8.2 [1] |
 | Jak-IN-1 | IC50 | 0.26 [1], 0.3 [2] |
 | 6-Anilino-4-(benzylamino)pyridine-3-carboxamide | IC50 | 4.5 [1], 5.0 [2] |
 | Jak3-IN-6 | IC50 | 0.15 [1], 4.0 [2] |
 | 3-((1H-Pyrrol-2-yl)methylene)-5-(pyridin-3-yl)indolin-2-one | IC50 | 27.0 [1], 38.0 [2] |
 | 4-Amino-N-methyl-2-phenylthieno[3,2-c]pyridine-7-carboxamide | IC50 | 767.0 [1], 25000.0 [2] |
 | 1-[(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]prop-2-en-1-one | IC50 | 75.0 [1], 1930.0 [2] |
 | (E)-1-[(3R)-3-(7H-Pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]but-2-en-1-one | IC50 | 1610.0 [1], 10000.0 [2] |
 | 1-[(3R)-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]prop-2-en-1-one | IC50 | 18.0 [1], 3840.0 [2] |
 | (E)-3-[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]-N,N-dimethylprop-2-enamide | IC50 | 22.0 [1], 51.0 [2] |
 | (E)-3-[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]prop-2-enenitrile | IC50 | 0.21 [1], 27.0 [2] |
 | 3-[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]propanenitrile | IC50 | 10.0 [1], 129.0 [2] |
 | [2-[6-(2-Ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-(4-fluorophenyl)methanone | IC50 | 0.6 [1], 1.7 [2] |
 | 1-[(3Ar,7aR)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridin-6-yl]ethanone | IC50 | 372.0 [1], 10000.0 [2] |
 | 9-Cycloheptyl-4,5-dimethoxy-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one | IC50 | 1.09 [1], 18340.0 [2] |
 | 9-Cyclooctyl-4,5-dimethoxy-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one | IC50 | 1.01 [1], 28860.0 [2] |
 | 4,5-Dimethoxy-9-(1-methylpiperidin-4-yl)-9,14,16-triazatetracyclo[8.7.0.02,7.011,15]heptadeca-1(17),2,4,6,10,12,15-heptaen-8-one | IC50 | 124.1 [1], 61570.0 [2] |
 | 2-[[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]methylidene]propanedinitrile | IC50 | 0.39 [1], 4.0 [2] |
 | 3-[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]-N,N-dimethylpropanamide | IC50 | 48.0 [1], 181.0 [2] |
 | 3-[5-(3-Cyclohexyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl)furan-2-yl]-2-(4-methylpiperazine-1-carbonyl)prop-2-enenitrile | IC50 | 0.74 [1], 14.0 [2] |
 | 1-[6-[5-(2-Methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1,4-benzoxazin-4-yl]prop-2-en-1-one | IC50 | 0.5 [1], 49.0 [2] |
 | [(1R,2R)-2-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 13.0 [1], 1530.0 [2] |
 | Methyl-[6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 230.0 [1], 10000.0 [2] |
 | [(1R,2S)-2-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 6.0 [1], 603.0 [2] |
 | [(1R,2R)-2-Hydroxy-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 2.0 [1], 280.0 [2] |
 | [(4R)-6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-chromen-4-yl]cyanamide | IC50 | 26.0 [1], 6110.0 [2] |
 | [(1R)-6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 66.0 [1], 5820.0 [2] |
 | N-[(1R,3S)-3-(Cyanoamino)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-4-methoxybenzenesulfonamide | IC50 | 16.0 [1], 947.0 [2] |
 | [1-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydroinden-1-yl]cyanamide | IC50 | 1.0 [1], 92.0 [2] |
 | N-[(1R,3S)-3-(Cyanoamino)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2-methoxyethanesulfonamide | IC50 | 1.0 [1], 111.0 [2] |
 | [6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 6.0 [1], 711.0 [2] |
 | 6-[5-(2-Methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1,4-benzoxazine-4-carbonitrile | IC50 | 17.0 [1], 1226.0 [2] |
 | [6-[5-(2-Methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-3,4-dihydro-2H-chromen-4-yl]cyanamide | IC50 | 49.0 [1], 5828.0 [2] |
 | [(4S)-6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-chromen-4-yl]cyanamide | IC50 | 7.0 [1], 781.0 [2] |
 | [6-[5-(2-Methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 12.0 [1], 1592.0 [2] |
 | 3-Cyano-N-[(1R,3S)-3-(cyanoamino)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]benzenesulfonamide | IC50 | 14.0 [1], 468.0 [2] |
 | [6-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-chromen-4-yl]cyanamide | IC50 | 7.0 [1], 1211.0 [2] |
 | [(1S,3S)-3-Hydroxy-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]cyanamide | IC50 | 13.0 [1], 1338.0 [2] |
 | 4-Amino-2-(4-morpholin-4-ylphenyl)thieno[3,2-c]pyridine-7-carboxamide | IC50 | 18.0 [1], 25000.0 [2] |
 | (R)-3-(6-(1-(4-Chlorophenyl)ethylamino)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 81.0 [1], 11000.0 [2] |
 | 3-(6-(2-(4-Fluorophenyl)pyrrolidin-1-yl)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 86.0 [1], 3100.0 [2] |
 | (R)-3-(6-(2,3-Dihydro-1H-inden-1-ylamino)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 200.0 [1], 20000.0 [2] |
 | (R)-3-(6-(1-(4-Fluorophenyl)butylamino)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 10.0 [1], 2400.0 [2] |
 | (R)-3-(6-(1-(4-Fluorophenyl)-2-methylpropylamino)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 12.0 [1], 4100.0 [2] |
 | (R)-3-(6-(1-(4-Fluorophenyl)ethylamino)pyrimidin-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 7.0 [1], 3200.0 [2] |
 | Atropisomer 1 | IC50 | 1530.0 [1] |
| Atropisomer 1 | Ki | 0.01 [1] |
 | 3-[6-[[(1R)-1-(4-Fluorophenyl)propyl]amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyrimidin-2-amine | IC50 | 12.0 [1], 1900.0 [2] |
Calculator
